MedTrace Logo

Antiretroviral Therapy and Extreme Weight

NCT01805427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2013-12-06

No results posted yet for this study

Summary

The concentration of the third agent in antiretroviral therapy \[Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI), or boosted Protease inhibitor (PI) \] is different according to the body weight or body composition and therapeutic monitoring may be necessary in overweight HIV patients.

The investigators aim at measuring the individual trough concentrations of interest \[at steady state for NNRTI and boosted PI\] in overweight and normal weight HIV+ patients.

Conditions

  • HIV Infection

Sponsors & Collaborators

  • Hopital Lariboisière

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805427 on ClinicalTrials.gov